This included treatment-emerging depression, exacerbation of depressive symptoms, fluctuations in depressive mood, and other clinically pertinent depressive-related events expressly covered in the studies.Considering the possible expanded effect of the GLP-1 RAs in mood and the central nervous system, the secondary outcomes were anxiety, mood disorder, suicidal thoughts, and mood-related adverse events.To increase the comparability and exhaustiveness of our analysis and investigate possible mediating variables about psychiatric adverse events, we also released data about metabolic parameters including body weight, BMI, fasting blood glucose, and lipid profiles
Krutmann, J
Endocrinology 160 , 19501963 (2019)
Most of the research behind BPC-157 comes from preclinical studies focused on tissue repair, gut integrity, and inflammation, not on body fat reduction, appetite suppression, or metabolic rate
This is especially important if you are taking medications that affect the liver or immune system
2,3 Since then, multiple meta-analyses, using data collected from large-scale cardiovascular outcome trials and the U.S